Impact of Peanut Allergy on Quality of Life: Baseline Results From PALISADE, a Phase 3, Double-Blind, Placebo-Controlled Trial for AR101 Oral Immunotherapy

Journal of Allergy and Clinical Immunology - United States
doi 10.1016/j.jaci.2018.12.471
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Efficacy and Safety of AR101 in Peanut Allergy: Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE)

Journal of Allergy and Clinical Immunology
AllergyImmunology
2018English

Prevalence of Comorbidities With Peanut Allergy: Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE)

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial

Pediatrics
Child HealthPediatricsPerinatology
2018English

Estimating the Probability of Tolerating Each Challenge Dose of Peanut Protein at Exit Double-Blind, Placebo-Controlled Food Challenge: Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE) of AR101

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Accidental Exposures to Peanut and Other Food Allergens: Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE)

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

AR101 Oral Immunotherapy for Peanut Allergy

Pediatrics
Child HealthPediatricsPerinatology
2019English

Longer-Term Safety and Efficacy Measures of AR101 Oral Immunotherapy for Peanut Allergy: Results From a Phase 3 Follow-On Study

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Pnd152 - Impact of Inotersen on Generic Health-Related Quality of Life for Patients With Hattr Amyloidosis: Results From a Double-Blind Placebo-Controlled Trial

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pnd150 - Impact of Inotersen on Condition-Specific Quality of Life (Qol) for Patients With Hattr Amyloidosis: Results From a Double-Blind Placebo-Controlled Trial

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy